American Journal of Cardiology
Volume 103, Issue 12 , Pages 1663-1671 , 15 June 2009

Two-Year Results of Paclitaxel-Eluting Stents in Patients With Medically Treated Diabetes Mellitus from the TAXUS ARRIVE Program

  • John M. Lasala, MD, PhD

      Affiliations

    • Washington University School of Medicine, St. Louis, Missouri
    • ,
  • David A. Cox, MD

      Affiliations

    • Lehigh Valley Hospital, Allentown, Pennsylvania
    • ,
  • D. Lynn Morris, MD

      Affiliations

    • Albert Einstein Medical Center, Philadelphia, Pennsylvania
    • ,
  • Jeffrey A. Breall, MD, PhD

      Affiliations

    • Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, Indiana
    • ,
  • Paul D. Mahoney, MD

      Affiliations

    • Sentara Norfolk General Hospital, Norfolk, Virginia
    • ,
  • Phillip A. Horwitz, MD

      Affiliations

    • University of Iowa, Carver College of Medicine, Iowa City, Iowa
    • ,
  • Dinesh Shaw, MD

      Affiliations

    • Christus St. Frances Cabrini Hospital, Alexandria, Louisiana
    • ,
  • Kristin L. Hood, PhD

      Affiliations

    • Boston Scientific Corporation, Marlborough, Massachusetts
    • Corresponding Author InformationCorresponding author: Tel: 508-683-6662; fax: 508-683-5642
    • ,
  • Lazar Mandinov, MD, PhD

      Affiliations

    • Boston Scientific Corporation, Marlborough, Massachusetts
    • ,
  • Keith D. Dawkins, MD

      Affiliations

    • Boston Scientific Corporation, Marlborough, Massachusetts

Received 7 January 2009 ,Revised 5 February 2009 ,Accepted 5 February 2009.

References 

  1. Patterson C, Mapera S, Li HH, Madamanchi N, Hilliard E, Lineberger R, et al. Comparative effects of paclitaxel and rapamycin on smooth muscle migration and survival: role of AKT-dependent signaling. Arterioscler Thromb Vasc Biol. 2006;26:1473–1480
  2. Lasala JM, Cox DA, Dobies D, Muhlestein JB, Katopodis J, Revtyak G, et al. Usage patterns and 2-year outcomes with the TAXUS Express stent: results of the U.S. ARRIVE 1 registry. Catheter Cardiovasc Interv. 2008;72:433–445
  3. Lasala JM, Cox DA, Lewis SJ, Tadros PN, Haas RC, Schweiger MJ, Chhabra A, Untereker WJ, Starzyk RS, Mascioli SR, Dawkins KD, Baim DS. Expanded use of the TAXUS express stent: 2-year insights of safety from The 7500 Patient ARRIVE Registry Programme. EuroIntervention In press.
  4. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350:221–231
  5. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344–2351
  6. Carrozza JP, Kuntz RE, Fishman RF, Baim DS. Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus. Ann Intern Med. 1993;118:344–349
  7. West NE, Ruygrok PN, Disco CM, Webster MW, Lindeboom WK, O'Neill WW, et al. Clinical and angiographic predictors of restenosis after stent deployment in diabetic patients. Circulation. 2004;109:867–873
  8. Kirtane AJ, Ellis SG, Dawkins K, Colombo A, Grube E, Popma J, et al. Paclitaxel-eluting coronary stents in patients with diabetes mellitus: pooled analysis from 5 randomized trials. J Am Coll Cardiol. 2008;51:708–715
  9. Mahmud E, Bromberg-Marin G, Palakodeti V, Ang L, Creanga D, DeMaria A. Clinical efficacy of drug eluting stents in diabetic patients: a meta-analysis. J Am Coll Cardiol. 2008;51:2385–2395
  10. Machecourt J, Danchin N, Lablanche JM, Fauvel JM, Bonnet JL, Marliere S, et al. Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients: the EVASTENT Matched-Cohort Registry. J Am Coll Cardiol. 2007;50:501–508
  11. Weber FD, Schneider H, Wiemer M, Pfannebecker T, Tebbe U, Hamm CW, et al. Sirolimus eluting stent (Cypher) in patients with diabetes mellitus: results from the German Cypher Stent Registry. Clin Res Cardiol. 2008;97:105–109
  12. Kumar R, Lee TT, Jeremias A, Ruisi CP, Sylvia B, Magallon J, et al. Comparison of outcomes using sirolimus-eluting stenting in diabetic versus nondiabetic patients with comparison of insulin versus non-insulin therapy in the diabetic patients. Am J Cardiol. 2007;100:1187–1191
  13. Daemen J, Kuck KH, Macaya C, LeGrand V, Vrolix M, Carrie D, et al. Multivessel coronary revascularization in patients with and without diabetes mellitus: 3-year follow-up of the ARTS-II (Arterial Revascularization Therapies Study—part II) trial. J Am Coll Cardiol. 2008;52:1957–1967
  14. Hoffmann R, Stellbrink E, Schroder J, Grawe A, Vogel G, Blindt R, et al. Impact of the metabolic syndrome on angiographic and clinical events after coronary intervention using bare-metal or sirolimus-eluting stents. Am J Cardiol. 2007;100:1347–1352
  15. Kimura M, Mintz GS, Weissman NJ, Dawkins KD, Grube E, Ellis SG, et al. Meta-analysis of the effects of paclitaxel-eluting stents versus bare metal stents on volumetric intravascular ultrasound in patients with versus without diabetes mellitus. Am J Cardiol. 2008;101:1263–1268
  16. Elezi S, Kastrati A, Pache J, Wehinger A, Hadamitzky M, Dirschinger J, et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol. 1998;32:1866–1873
  17. Kannel WB, McGee DL. Diabetes and cardiovascular disease (The Framingham study). JAMA. 1979;241:2035–2038
  18. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229–234
  19. Garg P, Normand SL, Silbaugh TS, Wolf RE, Zelevinsky K, Lovett A, et al. Drug-eluting or bare-metal stenting in patients with diabetes mellitus: results from the Massachusetts Data Analysis Center Registry. Circulation. 2008;118:2277–2285
  20. Silva JA, Ramee SR, White CJ, Collins TJ, Jenkins JS, Nunez E, et al. Primary stenting in acute myocardial infarction: influence of diabetes mellitus in angiographic results and clinical outcome. Am Heart J. 1999;138:446–455
  21. Eberly LE, Cohen JD, Prineas R, Yang L. Impact of incident diabetes and incident nonfatal cardiovascular disease on 18-year mortality: the Multiple Risk Factor Intervention Trial experience. Diabetes Care. 2003;26:848–854
  22. Schramm TK, Gislason GH, Kober L, Rasmussen S, Rasmussen JN, Abildstrom SZ, et al. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation. 2008;117:1945–1954

 The ARRIVE 1 and ARRIVE 2 registries and this analysis were sponsored and funded by Boston Scientific Corporation, Natick, Massachusetts. Dr. Breall, Dr. Shaw, and Dr. Horwitz received grant support from Boston Scientific Corporation. Dr. Lasala, Dr. Cox, Dr. Morris, and Dr. Mahoney receive consulting fees from or serve on the advisory board to Boston Scientific Corporation. Dr. Hood, Dr. Dawkins, and Dr. Mandinov are full-time employees of Boston Scientific Corporation and have stock options or equity interest in Boston Scientific Corporation.

PII: S0002-9149(09)00590-6

doi: 10.1016/j.amjcard.2009.02.035

American Journal of Cardiology
Volume 103, Issue 12 , Pages 1663-1671 , 15 June 2009

Article Tools

* Image Usage & Resolution